A Study to Evaluate the Efficacy and Safety of AD-223
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 502 participants.
Also called NCT06052748
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 502 participants
- Sponsor
- Registry
-
NCT06052748
-
- Other papers using this trial's data
- Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT06052748. Randomized; double masking; primary purpose treatment. Start 2024-02-15 (actual); primary completion 2025-03-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of AD-223
- Condition
- Hypertension,Essential
- Intervention (Drug)
- AD-223A
- Intervention (Drug)
- AD-223B
- Intervention (Drug)
- AD-223C
- Intervention (Drug)
- AD-223A Placebo
- Intervention (Drug)
- AD-223B Placebo
- Intervention (Drug)
- AD-223C Placebo
- Lead sponsor
- Addpharma Inc.
Record details
- Record id
cardio:ct-nct06052748- Content hash
7ad1145b069890bb58b26cdb3e2480d4eaf7e002342f85f76d84c78106ae0a22